Three things: First, it's incredibly frustratin
Post# of 148174
(Total Views: 461)
Posted On: 06/03/2022 5:47:29 PM
Three things:
First, it's incredibly frustrating to see the FDA to bend/break the rules to approve EUA's for preferred/favored BP's. We need FDA officials tried and jailed for their corruption, but I have little hope.
Second, with no real treatment for NASH and liver disease, does this mean the playing field will be level for CYDY? Or will the FDA still torpedo our approval until BP can financially break us. Honestly, I don't know. If FDA officials have no fear of prosecution, why would they change?
Third, regarding Novavax' non-mRNA pedigree, that is a plus. However, I think it's meaningless to quote relative risk reduction - in this case, 90.4% - without mentioning the miniscule Absolute Risk Reduction of 1,23%. Would most people really be motivated to inject something with just 2 years of testing (vs the usual 5 - 10) just to gain a 1.23% risk reduction of infection for something as relatively benign (for the vast majority of healthy adults) as COVID 19?
Regardless, here's to some hopeful cancer news - any news? - next week.
First, it's incredibly frustrating to see the FDA to bend/break the rules to approve EUA's for preferred/favored BP's. We need FDA officials tried and jailed for their corruption, but I have little hope.
Second, with no real treatment for NASH and liver disease, does this mean the playing field will be level for CYDY? Or will the FDA still torpedo our approval until BP can financially break us. Honestly, I don't know. If FDA officials have no fear of prosecution, why would they change?
Third, regarding Novavax' non-mRNA pedigree, that is a plus. However, I think it's meaningless to quote relative risk reduction - in this case, 90.4% - without mentioning the miniscule Absolute Risk Reduction of 1,23%. Would most people really be motivated to inject something with just 2 years of testing (vs the usual 5 - 10) just to gain a 1.23% risk reduction of infection for something as relatively benign (for the vast majority of healthy adults) as COVID 19?
Regardless, here's to some hopeful cancer news - any news? - next week.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼